Current advancements in Aβ luminescent probes and inhibitors of Aβ aggregation.
Alzheimer's disease (AD) is a neurodegenerative disorder that severely jeopardizes the health of aging populations all over the world. According to the amyloid cascade hypothesis, the pathological progression of AD is associated with the formation of amyloid plaques in the brain, resulting from the aggregation of amyloid-β (Aβ) peptides. Over the past few years, vast efforts have been dedicated to the development of amyloid probes and inhibitors for the diagnosis and effective treatment of AD. We review here recent advancements in luminescent probes for the detection of Aβ peptide and fibrils, and the current development of small molecule inhibitors of Aβ aggregation. We also highlight the key features in each specific example, as well as review new ideas and strategies that are crucial for researchers in this field.
Department of Chemistry, Hong Kong Baptist University, Kowloon Tong, Hong Kong, China. edmondma@hkbu.edu.hk
Dik-Lung
DL
Ma
Daniel Shiu-Hin
DS
Chan
Victor Pui-Yan
VP
Ma
Ka-Ho
KH
Leung
Hai-Jing
HJ
Zhong
Chung-Hang
CH
Leung
D000544:Alzheimer Disease / Q000378:metabolism / Q000473:pathology; D016229:Amyloid beta-Peptides / Q000032:analysis / Q000378:metabolism*; D000818:Animals; D001921:Brain / Q000378:metabolism*; D006801:Humans; D049408:Luminescent Agents; D008163:Luminescent Measurements / Q000379:methods*
D016229:Amyloid beta-Peptides; D049408:Luminescent Agents